January 11, 2022
Features
42
1
Industry experts convene for discussion on new quality management systems.
January 11, 2022
Features
42
1
Government-led programs aim to attract scientists and offer resources to growing industry.
January 11, 2022
Features
42
1
Pharma moves beyond promoting products to increase recognition of company names.
January 11, 2022
Features
42
1
Employer-sponsored health plans create an increasingly cloudy path to access.
January 11, 2022
Features
42
1
Standard for reaching patients shifts with influx of new technology in post-COVID world.
January 11, 2022
Features
42
1
Pandemic lockdowns push pharma into brand-new era of social engagement.
January 11, 2022
Features
42
1
Oncology and rare disease are ready to reap the benefits of COVID drug development.
January 11, 2022
Features
42
1
Growing evidence supports psychoactive substances can successfully treat mental issues.
January 11, 2022
Features
42
1
As borders shut down during the pandemic, pharma learned some lessons about sourcing.
January 11, 2022
42
1
Supply chain issues, psychedelic medicines, immunotherapies, social engagement, telemedicine, access barriers, corporate branding, and the rise of Chinese biotech are industry topics that deserve a closer look as we head into the future.
January 11, 2022
Executive Profile
42
1
Myrtle Potter is no stranger to overcoming adversity. As CEO of Sumitovant Biopharma, she has used her entrepreneurship, determination, and inclusive attitude to help her persevere and achieve her highest goals while overseeing five companies—Myovant, Urovant, Enzyvant, Altavant, and Spirovant.
January 11, 2022
Finance
42
1
Brief summary of EY’s 2022 M&A Firepower report highlights trends.
January 11, 2022
Marketing
42
1
Need for greater transparency and access fuels Big Tech’s presence.
January 11, 2022
Technology
42
1
The constantly evolving world of data is forcing pharma companies to implement new strategies for improved structure.
January 11, 2022
Leadership
42
1
Questions grow over adding titles to the biopharma C-suite.
January 11, 2022
Global Report
42
1
Looks to address disconnect between registration and reimbursement.
January 11, 2022
Washington Report
42
1
Progress in 2022 will require nimble action across several fronts.
January 11, 2022
Issue PDF
42
1
Click the title above for a link to open the Pharmaceutical Executive January 2022 issue in an interactive PDF format.
January 04, 2022
Back Page
42
1
Christopher J. Calhoun pulls back the curtain on the mysterious biotech funding process.